OncoAlert 4Sight Abstracts to be Presented at #ESMO26
Phase 3 LEAP-012 Study of Lenvatinib + Pembrolizumab vs Dual Placebo With Transarterial Chemoembolization (TACE) for Unresectable Non-Metastatic Hepatocellular Carcinoma: Long-Term OS Results

@DrElkhoueiry
@ArndtVogel

🔬 Phase 3 (n=480): lenvatinib + pembrolizumab + TACE vs dual placebo + TACE in unresectable, non-metastatic HCC. Dual primary endpoints: PFS and OS. Long-term OS (IA3).
➡️ Median OS 40.4 vs 40.8 mo; HR 0.98 (0.76–1.26)
➡️ Median PFS 14.6 vs 10.2 mo; HR 0.70 (0.56–0.89)
➡️ Grade ≥3 TRAEs 72.2% vs 32.0%
✅ LEAP-012 met its primary endpoint for PFS but did not show OS benefit; a median OS of ~40 mo sets a new benchmark for trial design. #HCC

🎙️ Josep Llovet
👥 Masatoshi Kudo · Zhenggang Ren · Yabing Guo · Guohong Han · Hailan Lin · Jinfang Zheng · Sadahisa Ogasawara · Ji Hoon Kim · Haitao Zhao · Chuan Li · David Madoff · Mark Ghobrial · Tomokazu Kawaoka · René Gerolami · Masafumi Ikeda · Hiromitsu Kumada · Anthony El-Khoueiry · Arndt Vogel · Xiang Peng · Kalgi Mody · Corina Dutcus · Leonid Dubrovsky · Abby Siegel · Richard Finn

(4Sight Made from Abstracts publicly available at the ESMO website)

Pinging OncoAlert Faculty

@CathyEngMD, @BenWestphalen, @graokane, @NiuSanford,
, @GillSharlene, @pashtoonkasi, @DrVilmaPBarcia, @Erman_Akkus, @GIMedOnc, @UOzkerim, @MarioBalsaMD, @p_ciracimd, @DraMartinezLago, @DaisukeKotani, @Aiims1742, @ARosen380, @realbowtiedoc, @KoheiShitara,